Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death
Author:
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Neurology (clinical),Oncology
Link
http://academic.oup.com/neuro-oncology/article-pdf/7/2/189/13066112/NO007-02_09Wasserfallen.pdf
Reference31 articles.
1. Bloor, K., Drummond, M.F., Brada, M., and Rampling, R. (1998) High grade gliomas: Clinical outcomes, resource use and cost of care. Memorandum. University of York, Centre for Health Economics, Heslington, York, U.K.
2. Brada, M., Hoang-Xuang, K., Rampling, R., Dietrich, P.Y., Dirix, L.Y., Macdonald, D., Heimans, J.J., Zonnenberg, B.A., Bravo-Marques, J.M., Henriksson, R., Stupp, R., Yue, N., Bruner, J., Dugan, M., Rao, S., and Zaknoen, S. (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol.12,259 -266.
3. Brock, C.S., Newlands, E.S., Wedge, S.R., Bower, M., Evans, H., Colquhoun, I., Roddie, M., Glaser, M., Brampton, M.H., and Rustin, G.J. (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res.58,4363 -4367.
4. Chamberlain, M.C., and Kormanik, P.A. (1998) Practical guidelines for the treatment of malignant gliomas. West. J. Med.168,114 -120.
5. Dinnes, J., Cave, C., Huang, S., Major, K., and Milne, R. (2001) The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: A rapid and systematic review. Health Technol. Assess.5, 1-73.
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Healthcare spending versus mortality in central nervous system cancer: Has anything changed?;Neuro-Oncology Practice;2024-04-27
2. Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas;Pituitary;2022-08-27
3. Letter: Is the Stupp Protocol an Expensive and Unsustainable Standard of Care for Glioblastoma in Low- and Middle-Income Country Settings? A Call to Action!;Neurosurgery;2021-07-28
4. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist;Cell Death & Disease;2021-06-24
5. IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity;Journal for ImmunoTherapy of Cancer;2021-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3